Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 17, 2018. The document serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of American Depositary Shares (ADSs) |
| Instrument ISIN | US37733W1053 |
| Transaction Price | $38.47 per ADS |
| Volume | 28 ADSs |
| Transaction Date | October 12, 2018 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction involving the re-investment of dividends paid on October 11, 2018, into the Deferred Annual Bonus Plan Post-Tax.
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. The transaction was executed by Mr. B McNamara, CEO of GSK Consumer Healthcare, as part of a dividend reinvestment plan.
Investor Verification Points
- Verify the identity of the PDMR: Mr. B McNamara, CEO of GSK Consumer Healthcare.
- Confirm the transaction was an acquisition of 28 ADSs at $38.47 on October 12, 2018.
- Note that this transaction resulted from the automatic re-investment of dividends under the Deferred Annual Bonus Plan Post-Tax.
- Understand that this filing does not contain quarterly or annual financial results.